JAZZ

Jazz Pharmaceuticals plc (JAZZ) | Rumor.io

Jazz Pharmaceuticals

JAZZ

Attention (50-day avg)0%

Attention rank (50-day avg)#1,997

Bullish sentiment (50-day avg)100%

Price to earnings ratio16.3

Market capitalization15.5B

Earnings per share14.6

Dividend yield (TTM)—

Revenue (annual)4.3B

Net income (annual)-356.1M

Social

What share of all stock conversation is about JAZZ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 27

$JAZZ shares jumped nearly 30% after strong Q3 results, with positive progress in a cancer-drug clinical trial boosting investor optimism about near-term growth prospects.
Jazz Pharmaceuticals' Epidiolex topped $1B in annual sales, boosting revenue visibility and adding cannabinoid exposure, raising questions about whether this milestone merits a higher valuation.
Epidiolex sales hit $1.1B in 2025, growing 9% driven by strong demand and volume growth, with patent protection extended into the late 2030s securing revenue streams against generics.

Generated by AI

Sentiment

Of the messages about JAZZ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	91.87% -0.79
Bearish	—	—	—	8.13% +0.79

Bullish· Nov 17

$JAZZ is becoming very profitable, with the potential for more bolt-on deals, driving earnings to $11 in 2027.
The company's successful Phase 3 trial for its cancer drug Ziihera has brought fresh optimism to its cancer drug pipeline and prompted analyst upgrades.
$JAZZ has broken out with strong volume, RSI overdrive, and chart patterns indicating a potential "moon" within the next 12 months.

Bearish· May 9

Jazz Pharmaceuticals' stock is trading at 11 times its 2015 earnings, with no takeover premium.
Analysts have decreased their targets for Jazz Pharmaceuticals, with some reducing their estimates by as much as $35 per share.
The company's recent earnings report was met with a decrease in the midpoints of its 2014 earnings and revenue ranges, and its stock price has fallen in pre-market trading.

Generated by AI

Topics

Of the messages about JAZZ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	74.16%
Technical Analysis	—	—	—	16.03%
Analysts	—	—	—	6.83%
Controversies	—	—	—	1.15%
Earnings	—	—	—	0.91%
Macro	—	—	—	0.91%

Earnings· Mar 1

Jazz Pharmaceuticals' Q4 2022 earnings report missed expectations, with a loss of $0.07 per share and revenue of $972.12M, which was slightly below the estimated $975.87M.
The company's FY23 guidance was updated to $16.90-$17.85 EPS and revenue of $3.675-$3.875 billion.
Jazz Pharmaceuticals' Q4 2022 earnings report was a mixed bag, with revenue meeting expectations but earnings per share missing estimates by $1.19.

Analysts· Dec 3

Wells Fargo & Co reiterated an "Outperform" rating for Jazz Pharmaceuticals, with a price target of $186.
TheStreet upgraded Jazz Pharmaceuticals to a B- rating.
Barclays raised the price target for Jazz Pharmaceuticals to $200.00, citing a strong outlook for the company.

Announcements· Nov 17

Jazz Pharmaceuticals' $JAZZ shares rose 13.4% to $160 premarket after the company announced its drug Ziihera met main goals in a late-stage study for stomach cancer treatment.
Ziihera showed promising results in a Phase 3 trial, with significant improvements in progression-free and overall survival compared to trastuzumab, and plans to submit a supplemental Biologics License Application in H1 2026.
The Q3 earnings report drove revenue growth primarily through sales of oncology and neurology drugs, with accelerated FDA approval for new drugs Modeyso and Zepzelca expected to boost pipeline expansion.

Generated by AI

Community

Of the messages about JAZZ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	40.45%
Newcomers	—	—	100%	59.55%

Regulars· Nov 17

Jazz Pharmaceuticals' Ziihera drug, in combination with chemotherapy, met the main goals in a late-stage study for stomach cancer treatment, showing promise in the field.
The company's stock price rose 13.4% to $160 premarket, following the positive study results.
Jazz Pharmaceuticals and Zymeworks are set to submit a biologics license application in H1 2026 for Ziihera as a first-line treatment for a specific type of stomach cancer.

Newcomers· Nov 17

Newcomers to the stock market are focusing on the potential for biotech stocks like $JAZZ to "moon" within the next 12 months.
Analysts are valuing $JAZZ at around $136, with some seeing it as ~19% overvalued at current levels, citing concerns about the company's competitive moat.
The Q3 earnings report for $JAZZ showed revenue growth driven by sales of oncology and neurology drugs, with accelerated FDA approval for new drugs expected to boost pipeline expansion.

Generated by AI

Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference. Chumi Khurana, senior vice president of U.S. Oncology

9d agoYahoo Finance

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Zii

9d agoYahoo Finance

Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet

12d agoYahoo Finance

Jazz Pharmaceuticals at Morgan Stanley conference: oncology drives growth

13d agoInvesting.com

Jazz Pharmaceuticals at Deutsche Bank 2026 Healthcare Summit: ziihera drives growth

13d agoInvesting.com

Also Discussed

Investors talking about JAZZ also mention

#	Name	Attention
1	AVDL - Avadel Pharmaceuticals plc	——
2	Incyte Corp.INCY	0%new
3	Anika Therapeutics Inc.ANIK	0%new
4	Alkermes plcALKS	0%0
5	Biogen IncBIIB	0%-0.01
6	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
7	BioMarin Pharmaceutical IncBMRN	0%+0
8	Nu Skin Enterprises Inc.NUS	0%0
9	Ionis Pharmaceuticals, Inc.IONS	0%new
10	Amgen Inc.AMGN	0.01%+0

Jazz Pharmaceuticals plc

Healthcare
Biotechnology

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious and often underserved conditions. Its portfolio includes treatments for sleep disorders, epilepsy, oncology, and other specialized therapeutic areas, with products such as Xywav, Epidiolex, Zepzelca, Rylaze, and Vyxeos supporting patients who may have limited treatment options. Jazz Pharmaceuticals plc works across the United States, Europe, and other international markets, serving healthcare providers, hospitals, and patients through prescription medicines and specialty care solutions. The company emphasizes rare disease and oncology medicines, making it an important participant in the global specialty pharmaceutical market. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals plc maintains a focused business model centered on identifying, developing, and commercializing targeted therapies for complex medical needs.

Website

Location

Waterloo Exchange

Dublin, D04 E5W7

Ireland

Social

What share of all stock conversation is about JAZZ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 27

$JAZZ shares jumped nearly 30% after strong Q3 results, with positive progress in a cancer-drug clinical trial boosting investor optimism about near-term growth prospects.
Jazz Pharmaceuticals' Epidiolex topped $1B in annual sales, boosting revenue visibility and adding cannabinoid exposure, raising questions about whether this milestone merits a higher valuation.
Epidiolex sales hit $1.1B in 2025, growing 9% driven by strong demand and volume growth, with patent protection extended into the late 2030s securing revenue streams against generics.

Generated by AI

Sentiment

Of the messages about JAZZ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	91.87% -0.79
Bearish	—	—	—	8.13% +0.79

Bullish· Nov 17

$JAZZ is becoming very profitable, with the potential for more bolt-on deals, driving earnings to $11 in 2027.
The company's successful Phase 3 trial for its cancer drug Ziihera has brought fresh optimism to its cancer drug pipeline and prompted analyst upgrades.
$JAZZ has broken out with strong volume, RSI overdrive, and chart patterns indicating a potential "moon" within the next 12 months.

Bearish· May 9

Jazz Pharmaceuticals' stock is trading at 11 times its 2015 earnings, with no takeover premium.
Analysts have decreased their targets for Jazz Pharmaceuticals, with some reducing their estimates by as much as $35 per share.
The company's recent earnings report was met with a decrease in the midpoints of its 2014 earnings and revenue ranges, and its stock price has fallen in pre-market trading.

Generated by AI

Topics

Of the messages about JAZZ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	74.16%
Technical Analysis	—	—	—	16.03%
Analysts	—	—	—	6.83%
Controversies	—	—	—	1.15%
Earnings	—	—	—	0.91%
Macro	—	—	—	0.91%

Earnings· Mar 1

Jazz Pharmaceuticals' Q4 2022 earnings report missed expectations, with a loss of $0.07 per share and revenue of $972.12M, which was slightly below the estimated $975.87M.
The company's FY23 guidance was updated to $16.90-$17.85 EPS and revenue of $3.675-$3.875 billion.
Jazz Pharmaceuticals' Q4 2022 earnings report was a mixed bag, with revenue meeting expectations but earnings per share missing estimates by $1.19.

Analysts· Dec 3

Wells Fargo & Co reiterated an "Outperform" rating for Jazz Pharmaceuticals, with a price target of $186.
TheStreet upgraded Jazz Pharmaceuticals to a B- rating.
Barclays raised the price target for Jazz Pharmaceuticals to $200.00, citing a strong outlook for the company.

Announcements· Nov 17

Jazz Pharmaceuticals' $JAZZ shares rose 13.4% to $160 premarket after the company announced its drug Ziihera met main goals in a late-stage study for stomach cancer treatment.
Ziihera showed promising results in a Phase 3 trial, with significant improvements in progression-free and overall survival compared to trastuzumab, and plans to submit a supplemental Biologics License Application in H1 2026.
The Q3 earnings report drove revenue growth primarily through sales of oncology and neurology drugs, with accelerated FDA approval for new drugs Modeyso and Zepzelca expected to boost pipeline expansion.

Generated by AI

Community

Of the messages about JAZZ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	40.45%
Newcomers	—	—	100%	59.55%

Regulars· Nov 17

Jazz Pharmaceuticals' Ziihera drug, in combination with chemotherapy, met the main goals in a late-stage study for stomach cancer treatment, showing promise in the field.
The company's stock price rose 13.4% to $160 premarket, following the positive study results.
Jazz Pharmaceuticals and Zymeworks are set to submit a biologics license application in H1 2026 for Ziihera as a first-line treatment for a specific type of stomach cancer.

Newcomers· Nov 17

Newcomers to the stock market are focusing on the potential for biotech stocks like $JAZZ to "moon" within the next 12 months.
Analysts are valuing $JAZZ at around $136, with some seeing it as ~19% overvalued at current levels, citing concerns about the company's competitive moat.
The Q3 earnings report for $JAZZ showed revenue growth driven by sales of oncology and neurology drugs, with accelerated FDA approval for new drugs expected to boost pipeline expansion.

Generated by AI

Jazz Pharmaceuticals

Social

Feb 27

Bullish· Nov 17

Bearish· May 9

Earnings· Mar 1

Analysts· Dec 3

Announcements· Nov 17

Regulars· Nov 17

Newcomers· Nov 17

Goldman Sachs initiates Jazz Pharmaceuticals stock with buy rating

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet

Jazz Pharmaceuticals at Morgan Stanley conference: oncology drives growth

Jazz Pharmaceuticals at Deutsche Bank 2026 Healthcare Summit: ziihera drives growth

Also Discussed

Jazz Pharmaceuticals plc

Company Information

Location

Goldman Sachs initiates Jazz Pharmaceuticals stock with buy rating

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands

Jazz Pharmaceuticals (JAZZ) Places An $820M Epilepsy Bet

Jazz Pharmaceuticals at Morgan Stanley conference: oncology drives growth

Jazz Pharmaceuticals at Deutsche Bank 2026 Healthcare Summit: ziihera drives growth

Also Discussed

Social

Feb 27

Bullish· Nov 17

Bearish· May 9

Earnings· Mar 1

Analysts· Dec 3

Announcements· Nov 17

Regulars· Nov 17

Newcomers· Nov 17